SJ

Sanjay Jamliya

Active Director Designated Partner DIN 10646811
DIN 10646811 First appointment Jun 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Sanjay Jamliya

Data last updated:

Sanjay Jamliya is a Designated Partner at Aardita Pharmaceutical Llp (since 2024).

DIN 10646811
Primary Designation Designated Partner
First Appointment 01 Jun 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner01 Jun 20242024Active

Board colleagues of Sanjay Jamliya

NameDINCompanyDesignation
Poonam Giri09639592Aardita Pharmaceutical LlpDesignated Partner
Urmita Sharma10646808Aardita Pharmaceutical LlpDesignated Partner
Vikas Singh06646554Aardita Pharmaceutical LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Aardita Pharmaceutical Llp
Premium access

Shareholding and investment profile for Sanjay Jamliya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sanjay Jamliya

Sanjay Jamliya currently holds 1 directorship: Aardita Pharmaceutical Llp (Designated Partner, since 01 Jun 2024).

Sanjay Jamliya was first appointed on 01 Jun 2024 as Designated Partner at Aardita Pharmaceutical Llp.

The current boards of Sanjay Jamliya's companies include Poonam Giri (Aardita Pharmaceutical Llp), Urmita Sharma (Aardita Pharmaceutical Llp), Vikas Singh (Aardita Pharmaceutical Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available